SCHEMBL30457618

SCHEMBL30457618

CCCCC/C=C\CCC(C=O)CCCCCCCCCCCCCC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 4/20 0.55
TRPV1 Q8NER1 2/20 0.55
TSHR P16473 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
TERT O14746 3/20 0.44
PTPN1 P18031 3/20 0.44
PPARG P37231 3/20 0.44
PPARD Q03181 3/20 0.44
PPARA Q07869 3/20 0.44
CYP1A2 P05177 2/20 0.44
MAPT P10636 2/20 0.44
CYP2C19 P33261 2/20 0.44
BLM P54132 2/20 0.44
HSD17B10 Q99714 2/20 0.44
FABP4 P15090 2/20 0.44
KMT2A Q03164 2/20 0.44
GMNN O75496 1/20 0.44
USP2 O75604 1/20 0.44
LMNA P02545 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1840042 1.00 FAAH (0.55) FAAHTRPV1TSHRSMN1; SMN2TERT
SCHEMBL17062960 1.00 FAAH (0.55) FAAHTRPV1TSHRSMN1; SMN2TERT
SCHEMBL27886133 1.00 FAAH (0.55) FAAHTRPV1TSHRSMN1; SMN2TERT
SCHEMBL17062961 1.00 FAAH (0.55) FAAHTRPV1TSHRSMN1; SMN2TERT
SCHEMBL17062952 0.98 FAAH (0.52) FAAHTRPV1TSHRSMN1; SMN2TERT
SCHEMBL17062953 0.98 FAAH (0.52) FAAHTRPV1TSHRSMN1; SMN2TERT
SCHEMBL7719569 0.96 FAAH (0.59) FAAHTRPV1TSHRSMN1; SMN2TERT
SCHEMBL10410016 0.96 FAAH (0.59) FAAHTRPV1TSHRSMN1; SMN2TERT
SCHEMBL7719572 0.96 FAAH (0.59) FAAHTRPV1TSHRSMN1; SMN2TERT
SCHEMBL10382124 0.96 FAAH (0.59) FAAHTRPV1TSHRSMN1; SMN2TERT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4731258-A1 LIPID NANOPARTICLES CONTAINING DISULFIDE LIPIDS AND FORMULATIONS THEREOF Providence Therapeutics Holdings Inc. (CA) 2026-04-29 EP disclosed
WO-2025076625-A1 GLUTAMIC ACID-BASED LIPIDS, LIPID NANOPARTICLE CONTAINING GLUTAMIC ACID-BASED LIPIDS, AND FORMULATIONS THEREOF PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) 2025-04-17 WO disclosed
US-20250073164-A1 IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) 2025-03-06 US disclosed
WO-2024259531-A1 LIPID NANOPARTICLES CONTAINING DISULFIDE LIPIDS AND FORMULATIONS THEREOF PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) 2024-12-26 WO disclosed
EP-4452934-A1 IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM Providence Therapeutics Holdings Inc. (CA) 2024-10-30 EP disclosed
WO-2023115221-A1 IONIZABLE DILSULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) 2023-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250073164-A1 IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM SGMS1, SGMS2, ABCB4 FAAH 3070/4885TRPV1 999/4885TSHR 2325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.